司来吉兰联合左旋多巴治疗帕金森病的临床效果观察  

Clinical Effect of Selegiline Combined with Levodopa in the Treatment of Parkinson's Disease

作　　者：余军伟 YU Junwei(Department of Neurology,Henan Shenhuo Group General Hospital,Shangqiu Henan 476600,China)

机构地区：[1]河南神火集团总医院神经内科,河南商丘476600

出　　处：《临床研究》2023年第1期74-77,共4页Clinical Research

摘　　要：目的探究帕金森患者经司来吉兰与左旋多巴联合治疗后的临床疗效,并观察其对患者精神状况及认知功能的影响。方法选取河南神火集团总医院2020年1月至2021年2月收治的72例帕金森患者为探究对象,依据随机数字表法,将入选患者归为联合组与单独组各36例。单独组采用左旋多巴治疗,联合组采用左旋多巴+司来吉兰联合治疗。观察两组患者治疗有效率,比较两组患者治疗前后认知功能、综合症状、精神状态水平,比较两组患者治疗前后血清指标,不良反应及生存质量。结果联合组患者治疗有效率(94.44)显著高于单独组(75.00),差异有统计学意义(P<0.05)。两组患者治疗前MOCA、UPDRS、MMSE评分差异无统计学意义(P>0.05);治疗后,两组患者UPDRS评分低于治疗前,MMSE、MOCA评分高于治疗前,且联合组UPDRS评分低于单独组,MMSE、MOCA评分高于单独组,差异有统计学意义(P<0.05)。两组患者治疗前Aβ1-42、Hcy水平差异无统计学意义(P>0.05),治疗后Aβ1-42水平升高,Hcy水平降低,且联合组Aβ1-42水平高于单独组,Hcy水平低于单独组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,联合组生活质量各维度评分均高于单独组,差异有统计学意义(P<0.05)。结论在帕金森患者应用司来吉兰+左旋多巴治疗后可获得理想的临床疗效,两种药物协同作用较强,不增加不良反应,可改善帕金森患者的认知功能及精神状态,缓解症状,改善患者生活质量,安全有效。Objective To investigate the clinical efficacy of selegiline combined with levodopa in patients with Parkinson's disease,and to observe its effects on patients'mental status and cognitive function.Methods A total of 72 patients with Parkinson's disease admitted to the General Hospital of Henan Shenhuo Group from January 2020 to February 2021 were selected as research objects.According to the random number table method,the patients were divided into the combined group and the single group,with 36 cases in each group.The single group was treated with levodopa,and the combination group was treated with levodopa+Selegiline.The effective rate of treatment in the two groups was observed,the cognitive function,comprehensive symptoms and mental state of the two groups were compared before and after treatment,and the serum indexes,adverse reactions and quality of life of the two groups were compared before and after treatment.Results The effective rate of combination group(94.44)was significantly higher than that of single group(75.00),and the difference was statistically significant(P<0.05).There was no significant difference in MOCA,UPDRS and MMSE scores between the two groups before treatment(P>0.05).After treatment,UPDRS scores in 2 groups were lower than before treatment,MMSE and MOCA scores were higher than before treatment,and UPDRS scores in combination group were lower than those in single group,while MMSE and MOCA scores were higher than those in single group,with statistical significance(P<0.05).There was no significant difference in Aβ1-42 and Hcy levels between the two groups before treatment(P>0.05),but Aβ1-42 levels increased and Hcy levels decreased after treatment,and Aβ1-42 levels in combination group were higher than those in single group,and Hcy levels were lower than those in single group,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,scores of all dimensions of quality of life in combina

关 键 词：司来吉兰 左旋多巴 帕金森 临床疗效 安全性 认知功能 精神状态 

分 类 号：R971.5[医药卫生—药品]